Insomnia Treatment Guidelines with Gabapentin and Hydroxyzine

Introduction to Treatment Options

The American Academy of Sleep Medicine recommends zolpidem 5 mg as first-line pharmacotherapy for insomnia, particularly for women and elderly patients to minimize next-day impairment 1
Low-dose doxepin 3-6 mg is preferred for sleep maintenance insomnia, providing 26-32 minutes improvement in total sleep time with minimal anticholinergic effects at these low doses 1
Ramelteon 8 mg has no dependence potential and no DEA scheduling, making it particularly useful if substance use history exists 1

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as first-line treatment 4
Short/intermediate-acting BzRAs (zolpidem, eszopiclone, zaleplon) or ramelteon are recommended as first-line pharmacotherapy 4
Alternative BzRAs or ramelteon are recommended if initial agent is unsuccessful 4
Sedating antidepressants (low-dose doxepin, trazodone, mirtazapine) are recommended as third-line, especially with comorbid depression/anxiety 4
Other agents (including antihistamines like hydroxyzine) are recommended only after other options have failed 2

The American Academy of Sleep Medicine's 2008 guideline states that antihistamines (including hydroxyzine) have "very limited" evidence for efficacy and safety, with "potential for serious side effects arising from their concurrent anticholinergic properties" 2
Long-term use of over-the-counter antihistamine treatments is not recommended due to limited safety and efficacy data 2
Gabapentin and hydroxyzine may require renal dose adjustment in patients with kidney disease 1
Use of hydroxyzine should be for the shortest duration possible (ideally 2-4 weeks maximum) 3